Rangeley Capital, LLC Arbutus Biopharma Corp Transaction History
Rangeley Capital, LLC
- $83.8 Billion
- Q2 2025
A detailed history of Rangeley Capital, LLC transactions in Arbutus Biopharma Corp stock. As of the latest transaction made, Rangeley Capital, LLC holds 865,000 shares of ABUS stock, worth $3.86 Million. This represents 3.19% of its overall portfolio holdings.
Number of Shares
865,000
Previous 1,349,000
35.88%
Holding current value
$3.86 Million
Previous $4.71 Billion
43.23%
% of portfolio
3.19%
Previous 5.04%
Shares
3 transactions
Others Institutions Holding ABUS
# of Institutions
182Shares Held
118MCall Options Held
1MPut Options Held
478K-
Morgan Stanley New York, NY24.2MShares$108 Million0.01% of portfolio
-
Whitefort Capital Management, LP New York, NY13.3MShares$59.5 Million14.31% of portfolio
-
Black Rock Inc. New York, NY11.6MShares$51.5 Million0.0% of portfolio
-
Two Seas Capital LP Rye, NY10.4MShares$46.6 Million0.6% of portfolio
-
Vanguard Group Inc Valley Forge, PA9.09MShares$40.5 Million0.0% of portfolio
About Arbutus Biopharma Corp
- Ticker ABUS
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 149,951,008
- Market Cap $669M
- Description
- Arbutus Biopharma Corporation, a biopharmaceutical company, develops novel therapeutics for chronic Hepatitis B virus (HBV) infection, SARS-CoV-2, and other coronaviruses in the United States. Its HBV product pipeline consists of AB-729, a proprietary subcutaneously delivered RNA interference product candidate, which in Phase Ia/Ib clinical tria...